Immunogenic oncolysis by tigilanol tiglate

Related Experiment Video

Updated: Jun 25, 2025

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.5K

Jonathan G Pol1,2, Manuela Lizarralde-Guerrero1,2,3, Guido Kroemer1,2,4

  • 1Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris Cité, Sorbonne Université, Paris, France.

Oncoimmunology
|May 30, 2024
PubMed

Insights

Tigilanol tiglate, a pyroptosis inducer, triggers immunogenic cell death in cancers. It also enhances the effectiveness of immune checkpoint inhibitors like CTLA-4 and PD-1 when injected into tumors.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Tigilanol tiglate is an investigational oncolytic small molecule.
  • Pyroptosis is a key mechanism in cancer cell death.

Purpose of the Study:

  • To investigate the immunogenic cell death (ICD) properties of tigilanol tiglate.
  • To assess the potential of tigilanol tiglate to sensitize tumors to immune checkpoint inhibitors.

Main Methods:

  • Tigilanol tiglate was studied for its ability to induce ICD hallmarks.
  • Subcutaneous cancer models were treated with tigilanol tiglate followed by immune checkpoint inhibitors.

Main Results:

  • Tigilanol tiglate demonstrated the capacity to induce key features of immunogenic cell death.
  • Intratumoral tigilanol tiglate administration sensitized tumors to CTLA-4 and PD-1 blockade.

Conclusions:

  • Tigilanol tiglate shows promise as an oncolytic agent that can enhance anti-tumor immunity.
  • Combination therapy with tigilanol tiglate and immune checkpoint inhibitors may represent a novel cancer treatment strategy.
Keywords:
Cancer immunosurveillanceimmunogenic cell deathintratumor immunotherapyoncolysistigilanol tiglate

More Related Videos

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.2K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

712

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
891
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K